Between August 1998 and July 1999, 21 patients received a novel protocol of reduced conditioning with fludarabine, carmustine and melphalan (FBM) followed by matched-related allogeneic peripheral blood stem cell transplantation (PBSCT) in a prospective multicenter phase I/II study. Cyclosporin A and 'minimethotrexate' were used for GVHD prophylaxis. Patients were included because of age, advanced disease, previous transplantation or co-morbidity. Hematopoietic engraftment after allogeneic transplantation was rapid with a median white blood count (WBC) Ͼ1 × lower relapse rate in patients with acute GVHD, a higher rate of relapse after T cell-depleted grafts and the possible reinduction of remission by infusion of donor lymphocytes (DLI) in different malignant diseases provide evidence for the GVM effect.
lower relapse rate in patients with acute GVHD, a higher rate of relapse after T cell-depleted grafts and the possible reinduction of remission by infusion of donor lymphocytes (DLI) in different malignant diseases provide evidence for the GVM effect. [1] [2] [3] [4] [5] The conditioning regimen is used to eradicate the malignancy and to allow engraftment by immunosuppression of the host. Further escalation of highdose radio-/chemotherapy may increase complete remission rates. However, due to extensive regimen-related toxicity, overall survival is not improved. 6, 7 In addition, a previous study from our group showed a significant contribution of conditioning-related inflammation to severity and outcome of GVHD. 8 In attempts to make allogeneic transplantation less toxic, it has been demonstrated in a canine model that substantial reduction of conditioning is sufficient to achieve engraftment. 9, 10 Based on such observations, new therapeutic approaches with reduced toxic conditioning regimens have been developed. [11] [12] [13] [14] Reduced conditioning regimens allow allogeneic transplantation to be performed with tolerable toxicity in a broad patient group, especially in patients older than 55 years or with comorbidities, with advanced disease and heavy pretreatment, with low-grade non-Hodgkin's lymphoma, or even with solid tumors, as reported for malignant melanoma or renal cell carcinoma. [11] [12] [13] [14] [15] [16] We used fludarabine instead of high-dose cyclophosphamide for T cell suppression and tolerance induction in the host and the combination of carmustine and melphalan as alkylating agents with high antineoplastic activity in a wide range of malignancies. Here, we present early follow-up data on chimerism and transplant-related toxicity of patients receiving this reduced conditioning protocol.
Patients and methods

Patient characteristics
Between August 1998 and July 1999, 21 adult patients with malignant diseases were treated with reduced conditioning and matched-related PBSCT in a prospective multicenter phase I/II trial approved by the internal review board and the ethics committee of the Albert-Ludwigs University Medical Center Freiburg and University Hospital Regensburg after written informed consent. Inclusion criteria were patients 18 to 65 years of age with advanced hematologic malignancies, progressive lymphomas, metastatic melanoma or renal cell carcinoma after standard-or second-line therapy. Exclusion criteria were severe organ dysfunction, active central nervous system (CNS) disease, infection with human immunodeficiency virus, active hepatitis B or C, creatinine Ͼ1.5 mg/dl, bilirubine Ͼ2.0 mg/dl or cardiac ejection fraction Ͻ50%. All consecutive patients enrolled are included in the present analysis. The median patient age was 51 years (range 38-59), with six patients 55 years or older. The underlying disease was lymphoma in 11, AML/MDS in four, CML/MPS in five and metastatic malignant melanoma in one, with advanced disease in 20/21 and one MPS patient with early disease but previous myocardial infarction prohibiting standard conditioning. The characteristics of the 21 patients are summarized in Table 1 . Data were analyzed as of 20 March 2000.
Conditioning regimen and transplantation procedure
As conditioning regimens, patients received reduced intensity treatment with fludarabine, carmustine and melphalan (FBM). ) and amsacrine (1 × 80 mg/m 2 ) (patient 4) or idarubicin weekly (patient 9) as induction therapy shortly before conditioning. Five lymphoma patients had a previous autologous PBSCT with BEAM in three and Bu/Cy or TBI/Cy, each in one. Cyclosporin A (5 mg/kg/day in twice daily divided doses from day −3 until 6 weeks post transplant and 10%/week tapering down thereafter) and 'mini-methotrexate' (5 mg/m 2 days +1, +3, +6) were used for GVHD prophylaxis. Acute GVHD was treated with additional prednisolone (2 × 1 mg/kg bw/day). All patients were transplanted with unmodified PBSC. Stem cell mobilization was performed as published with 2 × 10 g/kg/day rhuG-CSF (filgrastim) and leukapheresis was started on day 4. 17 In Regensburg, donors received 1 × 10 g/kg/day rhuG-CSF. Posttransplant administration of rhuG-CSF to facilitate engraftment is shown in Table 2 . Supportive care has been reported previously. 18 
Patient samples
Samples of BM or PB were taken from the recipient and donor prior to transplantation and from the recipient on days +15, +30, +100, +180, +270 and +360 or at individual time points of interest as part of the routine diagnostics. 
Chimerism analysis
Sex-independent chimerism analyses were done by VNTR-PCR. To screen for an informative marker that allows the distinctive discrimination between recipient and donor, genomic DNA was amplified by PCR with the highly polymorphic VNTR markers D1S80, 19 Tho1, 20 YNZ22, 21 ApoB, 22 D11S533, D17S30, F13A1 and IL2R␤ 23 under conditions given in the respective references. DNA isolation and analysis of PCR products by native 5-8% polyacrylamide or 2% agarose gel electrophoresis and silver or ethidium bromide staining were performed as described previously. 24 A locus was considered informative when a unique band for the recipient and a unique band for the donor or a unique band for the recipient only were found. A locus was uninformative if it failed to show a unique band for the recipient. Quantification was done densitometrically 23 with an ImageMaster VDS (Pharmacia, Freiburg, Germany) or by comparison with dilution experiments. The maximum sensitivity of the marker D1S80 to detect the absence of recipient-derived DNA as assessed by dilution experiments mixing varying percentages of recipient and donor DNA pretransplantation was 99% using a total of 100 ng genomic DNA for amplification. In one patient with transplantation from a different gender donor, chimerism was determined by interphase FISH using the Vysis CEP XY Kit (Xp11.1-q11.1, Yq12) (Vysis, Stuttgart, Germany) according to the manufacturer's protocol. Four hundred interphase nuclei were analyzed (sensitivity 99.4%). Mixed chimerism (MC) was defined as у1% of recipient derived cells or DNA. 25 
Results
PBSC mobilization, transplanted cell dose and hematopoietic engraftment
A median of two leukaphereses (range 1-3) were performed in allogeneic donors to harvest у4 × + numbers of 241.6 × 10 6 CD3 + cells/kg bw were transplanted (range 107.9-537.3) in 14 evaluated patients (Table 1 ). All patients showed rapid hematopoietic engraftment after allogeneic transplantation with a median white blood count (WBC) Ͼ1 × 10 9 /l on day +11 (range 10-17) for all patients and day +11 for patients with and day +15.5 without rhuG-CSF administration. A median platelet count Ͼ20 × 10 9 /l was reached on day +13 (range 9-36). Two patients developed pure red cell aplasia. Engraftment was defined as the first of 3 consecutive days of white blood cells Ͼ1 × 10 9 /l and platelets Ͼ20 × 10 9 /l independent of supportive platelet transfusions. The median duration of WBC Ͻ1 × 10 9 /l and platelets Ͻ20 × 10 9 /l was 13.5 days (range 0-25; n = 20; 12.5 days vs 17 days with or without G-CSF post transplant) and 8.5 days (range 4-21; n = 16), respectively. The curve of median WBC engraftment for patients receiving G-CSF from day + 5 or day +7 until engraftment (n = 16) and platelet engraftment (n = 20) is shown in Figure  1 . All patients received supportive transfusions with a median of eight red blood cell (RBC) transfusions (range 0-35) and a median of 21 platelet units (range 3-308). One patient had no need for RBC transfusions at all (Table 2) .
Chimerism
A total of 146 analyses were performed, 32/146 (22%) in BM samples and 114/146 (78%) in PB samples, with a median of seven (range 1-12) chimerism analyses post transplantation in each patient. In 16/21 (76%) patients complete donor chimerism (CC) was detected in BM or PB at all time points. Five out of 21 (24%) patients presented with mixed chimerism (MC) in BM or PB at least once post transplant with a median of 82% (range 5-100%) maximum recipient DNA in each patient. In two leukemia patients (patients 9 and 11) with PR and subsequent progressive disease (PD) an increased amount of recipient DNA was detectable. Two patients showed transient MC during CR, one AML patient (patient 14) and one patient with CLL (patient 1). Another CLL patient with initial MC and PR converted to CC and CR (patient 17). Enrichment of PB- 
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MNC and PB-Gran in 14 and lineage-specific cells in 10 CC patients did not lead to detection of MC in a certain cellular subset. The pattern of chimerism analyses is shown in Figure 2 for each patient.
Regimen-related toxicity
Thirteen patients developed mucositis with WHO grade 1 in 10 and grade 3 in three patients. Hepatic toxicity and renal impairment WHO grade 3 each occurred in one patient due to treatment of his aspergillosis with amphotericin B. This patient was transplanted in blast crisis and died 1 month post transplant with generalized aspergillosis and multi-organ failure despite rapid leukocyte engraftment. Transient hepatic toxicity WHO grade 3 occurred in a patient with previous autologous PBSCT and one heavily pretreated patient with malignant melanoma and liver metastasis. CSA-induced arterial hypertension occurred in one patient. We observed no other nonhematologic toxicity greater than WHO grade 2. Fever у37.5°C and neutropenia occurred in 15 patients, but rapidly resolved with antibiotic treatment. Four patients developed pneumonia or pneumonitis associated with aspergillus, herpes simplex virus type 1 (HSV1) and human herpes virus type 6 (HHV 6) in one patient each. One patient died due to interstitial pneumonia of unknown cause on day +243. Three patients developed central venous catheter infection. In one of these patients with a heterozygous factor V mutation, thrombosis of the ipsilateral jugular and subclavian vein occurred. Two patients were diagnosed with sepsis, which developed in one patient 1 month after appendicitis and neutropenia with post-operative subileus but responded to therapy, whereas the other patient with additional aGVHD died. CMV reactivation without clinical disease appeared in five patients, and gastrointestinal CMV infection in one patient. In all cases preemptive therapy with ganciclovir or foscarnet was successful.
GVHD
Acute GVHD grade I developed in three (skin), grade II in seven (skin, gut, liver), grade III in four (skin, gut, liver) and grade IV in two patients (skin, gut) (grades II-IV 62%). Interestingly, two patients showed clinical aGVHD later than day +100 post transplantation. Two patients died due to aGVHD. Limited chronic GVHD occurred in five and extensive chronic GVHD in nine out of 17 evaluable patients (Table 2) .
Response and overall survival
Most patients (19/21; 90%) achieved CR (n = 15) or PR (n = 4) with a median patient follow-up of 300+ days (range 27-577) of all patients and 354+ (range 258-577) of patients alive at 20 March 2000. Eight out of 21 patients died resulting in an overall survival of 62% ( Figure 3 ) and 52% disease-free survival. The cause of death was relapse in one patient with follicular lymphoma and PD in one patient transplanted with refractory AML and one CML patient with blast crisis. The malignant melanoma patient, who initially showed mixed response with regression of her lymph node metastases, but persistent liver metastasis, displayed PD 3 months post transplant and subsequently died. As described above, one MPS patient died too early to assess response on day +27 due to generalized aspergillosis and three patients died in CR, one due to interstitial pneumonia and two due to severe aGVHD, one patient with AML secondary to MDS who also had sepsis, and one CML patient.
Discussion
In this study 20/21 patients with advanced malignancies and 1/21 patients with early disease but previous myocardial infarction received a novel fludarabine-based conditioning regimen as an attempt to reduce the toxicity of allogeneic transplantation. We performed this study to assess the feasibility of the protocol, engraftment, lymphohematopoietic chimerism, regimen-related toxicity, incidence of GVHD and response of the underlying malignancy.
Hematopoietic engraftment after PBSCT was rapid with a median WBC Ͼ1 × 10 9 /l on day +11 and a median platelet count Ͻ20 × 10 9 /l on day +13 confirming that fludarabine is sufficient for tolerance induction in the host. 11, 13 Moreover, there was no graft failure regarding WBC and only one patient who died on day +27 due to generalized aspergillosis did not reach a platelet count Ͼ20 × 10 9 /l. The two cases of pure red cell aplasia are most likely due to an autoimmune reaction caused by multiple RBC transfusions before allogeneic transplantation. Engraftment was similar compared to conventional myeloablative conditioning regimens and PBSCT with or without administration of rhuG-CSF post transplant. [26] [27] [28] [29] In patients undergoing reduced conditioning the occurrence of transient MC was expected to be more frequent compared to patients after myeloablative conditioning. Thus, monitoring the kinetics of donor cell engraftment in these patients by assessment of chimerism analysis is of utmost importance. 30 Compared to recently published regimens using fludarabine-based conditioning regimen, patients in our protocol rapidly achieved CC in 76% of the patients and 24% showed MC. [11] [12] [13] Two patients with advanced leukemia and PR followed by PD displayed increasing MC. Three patients had transient MC, two with CLL and one with AML. Two of these patients were already in CR early post transplant, whereas in one CLL patient decreased MC was accompanied by conversion from PR to CR, reflecting most likely an accelerated graftversus-malignancy (GVM) effect which is of special importance in low grade lymphomas which are incurable by chemotherapy alone. The use of PBSC instead of BM with its relatively large CD3 + cell content may have contributed to the high rate of CC, suggesting that a further reduction in treatment intensity and thereby toxicity can be pursued.
The treatment was generally well tolerated. Moreover, the FBM regimen allowed allogeneic transplantation for relapse after previous autologous transplantation without any major toxicity in four patients. One previously trans-planted patient experienced transient hepatic toxicity WHO grade 3, appendicitis and neutropenia with post-operative subileus and a sepsis responding to specific therapy, but eventually died due to relapse on day +159. Only one patient died due to multi-organ failure following generalized aspergillosis and amphotericin B treatment 1 month post transplant. The cause of death in six other patients was relapse or progressive disease and infection and/or severe aGVHD in three patients each.
Early achievement of CC may be beneficial for an effective GVM effect. On the other hand, early CC may be associated with a higher rate of aGVHD 31, 32 and indeed the incidence of aGVHD grades II-IV in our patient group was with 62%, even in this age group with a median of 51 years rather high. 33 Interestingly, two patients developed clinical aGVHD later than 3 months post transplant. Whether a time limited influence of fludarabine on the induction of tolerance between graft and host contributed to this late occurrence of aGVHD remains to be determined. In our follow-up study, patients will receive mycofenolat mofetil (MMF) instead of MTX to reduce the incidence of aGVHD. 34 The follow-up is still too short to make conclusive statements regarding cGVHD.
It is assumed that the GVM effect requires several weeks to eradicate the malignant disease. 35 The patients reported here showed early response by 2 to 4 weeks post transplant, indicating that our conditioning regimen exerts an effect on the malignant disease before the GVM effect was completely effective. However, this anti-tumor effect is not sufficient to control rapidly proliferating myeloid diseases as shown by the early relapses of refractory AML and CML blast crisis. This observation is in line with other reports on non-myeloablative conditioning regimens reporting early relapses of far advanced diseases.
11
One patient with malignant melanoma and mixed response with regression of her lymph node metastases but persistent liver metastasis received a local infusion of donor T cells into the liver vessels to avoid generalized effects, since she had also aGVHD grade I. Nevertheless, this patient died 3 months post transplant due to progressive disease. There has been no other attempt at DLI yet, mostly because of aGVHD.
Our therapy resulted in engraftment of donor cells with rapid hematologic recovery and early complete donor chimerism, little regimen-related toxicity and good response in advanced disease patients. Despite the limited follow-up time the results with the FBM protocol are promising and encouraging. While treatment-related toxicity appears to be reduced, further measures to reduce severe GVHD have to be instituted. With subsequent longer follow-up we will be able to further evaluate this protocol for specific disease entities.
